eISSN: 2081-2841
ISSN: 1689-832X
Journal of Contemporary Brachytherapy
Current Issue Archive Supplements Articles in Press Journal Information Aims and Scope Editorial Office Editorial Board Register as Author Register as Reviewer Instructions for Authors Abstracting and indexing Subscription Advertising Information Links
SCImago Journal & Country Rank

Interview with Professor Janusz Skowronek
ABS 2015
vol. 9
Original paper

Computed tomography-guided implantation of 125I seeds brachytherapy for recurrent multiple pulmonary oligometastases: initial experience and results

Jie Li, Lijuan Zhang, Wenhuan Xu, Teng Wang, Leyuan Zhou, Qigen Xie, Weiguo Wang, Yanyan Hua

J Contemp Brachytherapy 2017; 9, 2: 132–138
Online publish date: 2017/04/03
View full text
Get citation
JabRef, Mendeley
Papers, Reference Manager, RefWorks, Zotero
Purpose: To retrospectively evaluate the efficacy and safety of computed tomography (CT)-guided percutaneous interstitial brachytherapy using 125I radioactive seeds for multiple pulmonary metastatic tumors.

Material and methods: Between September 2013 and December 2015, 22 patients with multiple pulmonary metastases, who after conventional chemotherapy and trans-arterial chemoembolization (TACE) therapy were considered unable to withstand stereotactic body radiation therapy (SBRT), received CT-guided 125I brachytherapy. Clinical data were studied retrospectively. A planning target volume of 90% (D90) was 120-160 Gy for 125I seeds with an activity of 25.9 MBq. A CT-based evaluation performed 1, 2, and 6 months’ post-implantation enabled review of local control of tumors.

Results: Twenty-two patients with 65 pulmonary metastases successfully completed treatment. The mean value for D90 for implantation for 125I seeds was 132 Gy. Complete response (CR) + partial response (PR) was documented in 81.54%, 78.46%, and 78.46% of patients at 1, 2, and 6 months after implantation, respectively. Fourteen out of 22 patients had CR, 3 had PR, 2 had stable disease (SD), and 3 had progressive disease (PD). Most of the metastases (CR + PR + SD; 87.69% after 6 months) were controlled by implantation.

Conclusions: CT-guided 125I brachytherapy is a safe and effective treatment for multiple pulmonary metastatic tumors, and can achieve good short-term local control, so long as the radiation dose is sufficient.

brachytherapy, computed tomography, 125I, pulmonary metastatic tumors

Chen W, Zheng R, Zeng H et al. Annual report on status of cancer in China, 2011. Chin J Cancer Res 2015; 27: 2-12.
Yeo UJ, Taylor ML, Dunn L et al. A novel methodology for 3D deformable dosimetry. Med Phys 2012; 39: 2203-2213.
Li J, Xie QG, Wang WG et al. CT-guided implantation of 125I seeds (permanent brachytherapy) for metastatic tumors of the hepatic portal system: Effectiveness and safety in 13 patients. Brachytherapy 2016; 15: 224-230.
Wang G, Zhang F, Yang B et al. Feasibility and Clinical Value of CT-guided 125I Brachytherapy for Bilateral Lung Recurrences from Colorectal Carcinoma. Radiology 2016; 278: 897-905.
Hui EP, Leung SF, Au JS et al. Lung metastasis alone in nasopharyngeal carcinoma: a relatively favorable prognostic group. A study by the Hong Kong Nasopharyngeal Carcinoma Study Group. Cancer 2004; 101: 300-306.
Weichselbaum RR, Hellman S. Oligometastases revisited. Nat Rev Clin Oncol 2011; 8: 378-382.
Qu A, Wang H, Li J et al. Biological effects of 125I seeds radiation on A549 lung cancer cells: G2/M arrest and enhanced cell death. Cancer Invest 2014; 87: 209-217.
Stauder MC, Macdonald OK, Olivier KR et al. Early pulmonary toxicity following lung stereotactic body radiation therapy delivered in consecutive daily fractions. Radiother Oncol 2011; 99: 166-171.
Kang KH, Okoye CC, Patel RB et al. Complications from Stereotactic Body Radiotherapy for Lung Cancer. Cancers (Basel) 2015; 7: 981-1004.
Trakul N, Harris JP, Le QT et al. Stereotactic ablative radiotherapy for reirradiation of locally recurrent lung tumors. J Thorac Oncol 2012; 7: 1462-1465.
Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30: 52-60.
Lo SS, Moffattbruce SD, Dawson LA et al. The role of local therapy in the management of lung and liver oligometastases. Nat Rev Clin Oncol 2011; 8: 405-416.
Groeschl RT, Pilgrim CH, Hanna EM et al. Microwave ablation for hepatic malignancies: a multiinstitutional analysis. Ann Surg 2014; 259: 1195-1200.
Wong SL, Mangu PB, Choti MA et al. American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. J Clin Oncol 2010; 28: 493-508.
Parashar B, Arora S, Wernicke AG. Radiation Therapy for Early Stage Lung Cancer. Semin Intervent Radiol 2013; 30: 185-190.
Filosso PL, Sandri A, Oliaro A et al. Emerging treatment options in the management of non-small cell lung cancer. Lung Cancer: Targets and Therapy 2011; 2: 11-28.
Li W, Guan J, Yang L et al. Iodine-125 brachytherapy improved overall survival of patients with inoperable stage III/IV non-small cell lung cancer versus the conventional radiotherapy. Med Oncol 2015; 32: 395.
Li J, Yu M, Xiao Y et al. Computed tomography fluoroscopy-guided percutaneous 125I seed implantation for safe, effective and real-time monitoring radiotherapy of inoperable stage T1-3N0M0 non-small-cell lung cancer. Mol Clin Oncol 2013; 1: 1019-1024.
Jiang G, Li Z, Ding A et al. Computed tomography-guided iodine-125 interstitial implantation as an alternative treatment option for lung cancer. Indian J Cancer 2015; 51: 9-12.
Huang Q, Chen J, Chen Q et al. Computed tomographic- guided iodine-125 interstitial implants for malignant thoracic tumors. Eur J Radiol 2013; 82: 2061-2066.
Zhang L, Chen LH, Wang J et al. CT-guided radioactive 125I seed implantation treatment of multiple pulmonary metastases of hepatocellular carcinoma. Clin Radiol 2014; 69: 624-629.
Li C, Zhang F, Zhang W et al. Feasibility of 125I brachytherapy combined with sorafenib treatment in patients with multiple lung metastases after liver transplantation for hepatocellular carcinoma. J Cancer Res Clin Oncol 2010; 136: 1633-640.
Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe